Evidence map›Paper›PMID 40035761›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Hypercholesterolemia-induced LXR signaling in smooth muscle cells contributes to vascular lesion remodeling and visceral function.

Hanming Zhang, Diego Sáenz de Urturi, Pablo Fernández-Tussy, Yan Huang, Daniel G Jovin, Xinbo Zhang, Shushu Huang, Monkol Lek, Jonatas da Silva Catarino, Magdalena Sternak and 8 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hanming ZhangVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-5992-5433
Diego Sáenz de UrturiVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Pablo Fernández-TussyVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Yan HuangVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Daniel G JovinYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511.ORCID 0000-0002-8411-5942
Xinbo ZhangVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-9184-5767
Shushu HuangDeparment of Genetics, Yale University School of Medicine, New Haven, CT 06510.ORCID 0000-0002-0220-4395
Monkol LekDeparment of Genetics, Yale University School of Medicine, New Haven, CT 06510.
Jonatas da Silva CatarinoDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520.
Magdalena SternakVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Kathryn M CitrinVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Fillip K SwirskiCaridovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Jan-Åke GustafssonDepartment of Biology and Biochemistry, Center of Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204.ORCID 0000-0002-1472-1373
Daniel M GreifYale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511.ORCID 0000-0002-9842-3751
Enric EspluguesVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-8130-0413
Lauren A BiwerVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.
Yajaira SuárezVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0003-4549-2953
Carlos Fernández-HernandoVascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-3950-1924

Funding

Contribution of novel lysoplasmalogenases enzymes in regulating macrophage immunometabolic responses in cardiovascular diseaseR01HL171480 · NHLBI · YALE UNIVERSITY · PI Carlos Fernandez Hernando · 2024 to 2026
$2.3M
American Heart Association (AHA) 2021AHA000POST000216883American Heart Association-American Stroke Association 899129HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL171480-01A1NHLBI NIH HHS R01 HL171480
6 · The paper itself

Abstract

Vascular smooth muscle cells (VSMC) are the most abundant cell type in the artery's media layer and regulate vascular tone and lesion remodeling during atherogenesis. Like monocyte-derived macrophages, VSMCs accumulate excess lipids and contribute to the total intimal foam cell population in human coronary plaques and mouse aortic atheroma. While there are extensive studies characterizing the contribution of lipid metabolism in macrophage immunometabolic responses in atherosclerotic plaques, the role of VSMC lipid metabolism in regulating vascular function and lesion remodeling in vivo remains poorly understood. Here, we report that the liver X receptor (LXR) signaling pathway in VSMC is continuously activated during atherogenesis. Notably, we found that LXR deficiency in SMCs under hypercholesterolemic conditions influenced lesion remodeling by altering the fate of dedifferentiated SMCs and promoting the accumulation of VSMC-derived transitional cells. This phenotypic switching was accompanied by reduced indices of plaque stability, characterized by a larger necrotic core area and reduced fibrous cap thickness. Moreover, SMC-specific LXR deficiency impaired vascular function and caused visceral myopathy characterized by maladaptive bladder remodeling and gut lipid malabsorption. Mechanistically, we found that the expression of several genes involved in cholesterol efflux and FA synthesis including

Indexed as

AtherosclerosisHypercholesterolemiaLiver X ReceptorsMuscle, Smooth, VascularMyocytes, Smooth MuscleVascular RemodelingAnimalsHumansLipid MetabolismMaleMiceMice, Inbred C57BLMice, KnockoutPlaque, AtheroscleroticSignal TransductionLiver X Receptorsatheroslerosislipid metabolismnuclear receptorsvascular disease

Identifiers

PMID40035761
PMCPMC11912459

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.